妊娠期阿司匹林的药代动力学与药效学
本研究为前瞻性研究,纳入19名子痫前期高风险孕妇(孕早期数据19例,孕晚期16例),每日服用81 mg阿司匹林。孕早、晚期平均药代动力学参数无统计学显著变化,但孕晚期峰值浓度有降低趋势(P=.08)。基线肥胖和当前体重指数与峰值水杨酸浓度及0-6小时曲线下面积负相关。
要点
- 孕早、晚期81 mg阿司匹林平均药代动力学参数无统计学显著变化,孕晚期峰浓度有降低趋势(P=.08)。
- 基线肥胖和当前体重指数与峰值水杨酸浓度及0-6小时曲线下面积负相关。
- 血浆水杨酸浓度与尿血栓素抑制及血小板功能分析-100闭口时间延长相关。
核心结论
- 研究展示了单次81 mg阿司匹林在妊娠期间个体因素、血浆水杨酸浓度、血栓素抑制和血小板抑制之间的关系。
- 研究结果提示妊娠期调整阿司匹林剂量可能有助于达到最佳反应。
- 研究结果可用于促进计算建模,以考虑个体因素来确定最佳剂量。
研究设计与样本
- 前瞻性研究,纳入子痫前期高风险且建议每日服用81 mg阿司匹林的患者。
- 研究包含3次访视:基线孕早期(孕10-16周)6小时药代动力学访视,在开始阿司匹林前进行;随访1为开始阿司匹林后2至4周;随访2为孕晚期(孕28-32周)6小时药代动力学访视。
- 19名参与者有孕早期数据,16名有孕晚期数据。
主要发现
- 孕早期与孕晚期平均药代动力学参数无统计学显著变化,但孕晚期峰值浓度有低于孕早期的趋势(P=.08)。
- 多变量回归中,基线肥胖与对数调整的峰值水杨酸浓度负相关(-0.28 [-0.46至-0.11],P=.003),当前体重指数(连续变量)与对数调整的峰值水杨酸浓度负相关(-0.02 [-0.03至-0.009],P=.001)。
- 基线肥胖与对数调整的血浆水杨酸0至6小时曲线下面积负相关(-0.25 [-0.45至0.05],P=.02),当前体重指数与对数调整的血浆水杨酸0至6小时曲线下面积负相关(-0.04 [-0.07至-0.01],P=.008)。
- 开始阿司匹林后2至4周尿血栓素较基线显著下降,并与血小板功能分析-100闭口时间 concomitant 增加相关。
- 多变量回归模型中,血浆水杨酸浓度(0-6小时曲线下面积)与尿血栓素强相关(B=-3.12 [-5.38至-1.04],P=.006),与血小板功能分析-100相关(-0.23 [-0.31至-0.14],P<.001);随着血栓素抑制进展,血小板抑制(血小板功能分析-100闭口时间)增加。
临床怎么用
- 作者认为,妊娠期调整阿司匹林剂量可能有助于达到最佳反应。
- 作者认为,研究结果可用于促进计算建模,以考虑个体因素来确定最佳剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low dose aspirin is recommended for prevention of preeclampsia, however there is not consensus on the appropriate dose. Pregnancy specific changes have the potential to impact the pharmacology of aspirin in pregnancy, however there are very limited studies on aspirin pharmacokinetics in pregnancy and none linking pharmacokinetics (PK, drug dose and drug level) to pharmacodynamics (PD, drug dose and physiologic response) in pregnancy. As a result, we do not have a good understanding of the pharmacologic response to aspirin in pregnancy, which has important implications for clinical efficacy. We sought to describe the PK and PD of aspirin through pregnancy and to identify individual covariates that impacted aspirin PK/PD. OBJECTIVE: We sought to describe the PK and PD of aspirin through pregnancy (first and third trimester), to identify covariates that significantly impact aspirin PK and to identify the relationship between aspirin PK and PD. STUDY DESIGN: This is a prospective study of patients at high risk for preeclampsia recommended to take 81 mg aspirin daily. This study involved 3 visits as follows: (1) baseline, first trimester (10-16 weeks of gestation) 6-hour PK visit, done before initiation of aspirin; (2) follow-up 1: 2 to 4 weeks after aspirin initiation; and (3) follow-up 2: third trimester 6-hour PK visit (28-32 weeks of gestation). The following were assessed at each visit: weight or body mass index, platelet function analysis-100 (Siemens), urinary thromboxane B2, serum thromboxane B2, and plasma salicylic acid. The PK visits consisted of blood work done at baseline (predose), administration of 81 mg nonenteric coated aspirin, and then plasma blood level of salicylic acid assessed at 30 minutes and then hourly 1 to 6 hours after dose. Pearson correlation and multivariable regression were used to identify associations between parameters and identify relevant covariates. Log-adjusted values were used for regression analysis. P<.05 was considered statistically significant. RESULTS: Nineteen participants were included with first trimester data, and 16 with third trimester data. There was no statistically significant change in mean PK parameters between the first and third trimester, although there was a trend to lower peak concentration in the third than in the first trimester (P=.08). In multivariable regression, baseline obesity and current body mass index as a continuous measures were negatively associated with log-adjusted peak salicylic acid concentration (-0.28 [-0.46 to -0.11], P=.003 and -0.02 [-0.03 to -0.009], P=.001, respectively) and log-adjusted plasma salicylic acid area under the curve 0 to 6 hours postdose (-0.25 [-0.45 to 0.05], P=.02, -0.04 [-0.07 to -0.01], P=.008 respectively). There was a significant decrease in urinary thromboxane 2 to 4 weeks after aspirin initiation compared with baseline, which correlated with a concomitant increase in platelet function analysis-100 closure time. In multivariable regression model, there was a strong association between plasma salicylic acid concentration (area under the curve 0-6 hours postdose) and urinary thromboxane (B=-3.12 [-5.38 to -1.04], P=.006), and with urinary thromboxane suppression and platelet inhibition, platelet function analysis-100 (-0.23 [-0.31 to -0.14], P<.001). With progressive thromboxane suppression, platelet inhibition (platelet function analysis-100 closure time) increased. Individual comorbidities, including weight, hypertension, and pregestational diabetes (Type I or II), also impacted aspirin response. CONCLUSION: We have demonstrated the relationship between individual factors, plasma concentrations of salicylic acid, thromboxane suppression, and platelet inhibition at a single dose (81 mg) of aspirin taken through pregnancy. Our findings suggest that dose modification of aspirin in pregnancy may help to achieve the optimal response. Our results may be used to facilitate computational modeling to identify optimal dosing, taking into consideration individual factors.
引用
- Boelig RC, Kaushal G, Rochani A, et al. Aspirin pharmacokinetics and pharmacodynamics through gestation. Am J Obstet Gynecol. 2023. PMID: 38145726. doi:10.1016/j.ajog.2023.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。